Could immune checkpoint drugs tame a deadly brain virus?

NCT ID NCT07512518

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether immune checkpoint inhibitors, drugs that help the immune system fight infections, can improve outcomes for people with progressive multifocal leukoencephalopathy (PML), a rare brain virus. Researchers will follow 66 patients over a year, measuring disability, brain scans, and viral levels. The goal is to see if these drugs can control the infection and reduce long-term damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Immune checkpoint inhibitors (drugs that boost the immune system to fight viruses)
What this could lead to
If successful, this could point toward a new treatment for progressive multifocal leukoencephalopathy (PML), a rare and often fatal brain infection.
What could go wrong
This is a small, early-stage study with only 66 participants, so results may not apply to everyone. Immune checkpoint inhibitors can cause side effects like inflammation or autoimmune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC VIRAL INFECTION OF THE CENTRAL NERVOUS SYSTEM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.